Background Current diagnosis of antiphospholipid syndrome (APS) relies on antiphospholipid antibodies (aPL) testing, but false-positive aPL results and asymptomatic aPL carriers pose significant ...
Objectives Even in a lupus low disease activity state (LLDAS), many patients with SLE continue to face residual symptoms and disease burden. We aimed to evaluate the quality of life, activity ...
Objective Systemic lupus erythematosus (SLE) is a type of autoimmune disease that involves multiple organs involved as well as cytokine dysregulation. The treatment of SLE is still challenging due to ...
Introduction DNA hypomethylation in patients with systemic lupus erythematosus (SLE) has been recently documented in the literature. Low levels of DNA methylation have been observed globally and in ...
Objectives To compare two measures of systemic lupus erythematosus (SLE) response: the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus ...
Original research: Balancing stringency and feasibility: comparative value of disease-activity measures to predict pregnancy outcomes in systemic lupus erythematosus (22 January, 2026) ...
Objectives To explore the effects of anti-ribosomal P protein (anti-P) and anti-N-methyl-D-aspartic acid receptor subunit 2 (anti-NR2) autoantibodies on depression and cognitive dysfunction and their ...
Background The short-term and long-term outcome of inflammatory neuropsychiatric SLE (NPSLE) with immunosuppressive treatment is largely unknown. We used clinical data from our tertiary referral ...
Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...
Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...
Geraldino-Pardillaet al.1 recently published an interesting article analysing one of the most important aspects of systemic lupus erythematosus (SLE): the risk of cardiovascular disease, a leading ...
LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data (6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results